92 related articles for article (PubMed ID: 22388963)
1. In silico modeling of UDP-glucuronosyltransferase 1A10 substrates using the VolSurf approach.
Dong D; Wu B
J Pharm Sci; 2012 Sep; 101(9):3531-9. PubMed ID: 22388963
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR studies on UDP-glucuronosyltransferase 2B7 substrates using the pharmacophore and VolSurf approaches.
Ako R; Dong D; Wu B
Xenobiotica; 2012 Sep; 42(9):891-900. PubMed ID: 22494439
[TBL] [Abstract][Full Text] [Related]
3. Establishment of pharmacophore and VolSurf models to predict the substrates of UDP-glucuronosyltransferase1A3.
Wu Z; Zhang X; Ma Z; Wu B
Xenobiotica; 2015; 45(8):653-62. PubMed ID: 25837689
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
J Med Chem; 2003 Apr; 46(9):1617-26. PubMed ID: 12699380
[TBL] [Abstract][Full Text] [Related]
5. How many and which amino acids are responsible for the large activity differences between the highly homologous UDP-glucuronosyltransferases (UGT) 1A9 and UGT1A10?
Itäaho K; Laakkonen L; Finel M
Drug Metab Dispos; 2010 Apr; 38(4):687-96. PubMed ID: 20089735
[TBL] [Abstract][Full Text] [Related]
6. Mapping the UDP-glucuronic acid binding site in UDP-glucuronosyltransferase-1A10 by homology-based modeling: confirmation with biochemical evidence.
Banerjee R; Pennington MW; Garza A; Owens IS
Biochemistry; 2008 Jul; 47(28):7385-92. PubMed ID: 18570380
[TBL] [Abstract][Full Text] [Related]
7. The first aspartic acid of the DQxD motif for human UDP-glucuronosyltransferase 1A10 interacts with UDP-glucuronic acid during catalysis.
Xiong Y; Patana AS; Miley MJ; Zielinska AK; Bratton SM; Miller GP; Goldman A; Finel M; Redinbo MR; Radominska-Pandya A
Drug Metab Dispos; 2008 Mar; 36(3):517-22. PubMed ID: 18048489
[TBL] [Abstract][Full Text] [Related]
8. Molecular Docking-Based Design and Development of a Highly Selective Probe Substrate for UDP-glucuronosyltransferase 1A10.
Juvonen RO; Rauhamäki S; Kortet S; Niinivehmas S; Troberg J; Petsalo A; Huuskonen J; Raunio H; Finel M; Pentikäinen OT
Mol Pharm; 2018 Mar; 15(3):923-933. PubMed ID: 29421866
[TBL] [Abstract][Full Text] [Related]
9. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates.
Sorich MJ; Smith PA; McKinnon RA; Miners JO
Pharmacogenetics; 2002 Nov; 12(8):635-45. PubMed ID: 12439224
[TBL] [Abstract][Full Text] [Related]
10. Phenylalanine(90) and phenylalanine(93) are crucial amino acids within the estrogen binding site of the human UDP-glucuronosyltransferase 1A10.
Starlard-Davenport A; Xiong Y; Bratton S; Gallus-Zawada A; Finel M; Radominska-Pandya A
Steroids; 2007 Jan; 72(1):85-94. PubMed ID: 17174996
[TBL] [Abstract][Full Text] [Related]
11. Glucuronidation of bioflavonoids by human UGT1A10: structure-function relationships.
Lewinsky RH; Smith PA; Mackenzie PI
Xenobiotica; 2005 Feb; 35(2):117-29. PubMed ID: 16019943
[TBL] [Abstract][Full Text] [Related]
12. The uridine diphosphate glucuronosyltransferases: quantitative structure-activity relationships for hydroxyl polychlorinated biphenyl substrates.
Wang D
Arch Toxicol; 2005 Oct; 79(10):554-60. PubMed ID: 15889236
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinally distributed UDP-glucuronosyltransferase 1A10, which metabolizes estrogens and nonsteroidal anti-inflammatory drugs, depends upon phosphorylation.
Basu NK; Kubota S; Meselhy MR; Ciotti M; Chowdhury B; Hartori M; Owens IS
J Biol Chem; 2004 Jul; 279(27):28320-9. PubMed ID: 15117964
[TBL] [Abstract][Full Text] [Related]
14. Amino acid residue ILE211 is essential for the enzymatic activity of human UDP-glucuronosyltransferase 1A10 (UGT1A10).
Martineau I; Tchernof A; Bélanger A
Drug Metab Dispos; 2004 Apr; 32(4):455-9. PubMed ID: 15039300
[TBL] [Abstract][Full Text] [Related]
15. Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Cianchetta G; Mannhold R; Cruciani G; Baroni M; Cecchetti V
J Med Chem; 2004 Jun; 47(12):3193-201. PubMed ID: 15163198
[TBL] [Abstract][Full Text] [Related]
16. In silico insights: chemical and structural characteristics associated with uridine diphosphate-glucuronosyltransferase substrate selectivity.
Smith PA; Sorich MJ; McKinnon RA; Miners JO
Clin Exp Pharmacol Physiol; 2003 Nov; 30(11):836-40. PubMed ID: 14678246
[TBL] [Abstract][Full Text] [Related]
17. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity.
Sorich MJ; Miners JO; McKinnon RA; Smith PA
Mol Pharmacol; 2004 Feb; 65(2):301-8. PubMed ID: 14742671
[TBL] [Abstract][Full Text] [Related]
18. Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method.
Sorich MJ; McKinnon RA; Miners JO; Winkler DA; Smith PA
J Med Chem; 2004 Oct; 47(21):5311-7. PubMed ID: 15456275
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates.
Sorich MJ; Smith PA; Miners JO; Mackenzie PI; McKinnon RA
Curr Drug Metab; 2008 Jan; 9(1):60-9. PubMed ID: 18220572
[TBL] [Abstract][Full Text] [Related]
20. Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and 1A10.
Sten T; Qvisen S; Uutela P; Luukkanen L; Kostiainen R; Finel M
Drug Metab Dispos; 2006 Sep; 34(9):1488-94. PubMed ID: 16763014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
